Italian pharmacy online: cialis senza ricetta medica in farmacia.

Viral hepatitis: global policy

Viral Hepatitis: Global Policy - selected data Question
Questions 1-10
In your country, is there a written national
strategy…
Q1.a. Exclusive for viral hepatitis
Q1.b. only for hepatitis B
Q1.d. Integrated with other diseases
Q1.e. Do not know
Q1.1. Raising awareness
Q1.2. Surveil ance
Q1.3. Vaccination
Q1.4. Prevention in general
Q1.5. prevention of transmission of viral hepatitis via i…
Q1.6. Health care transmission prevention
Q1.7. Treatment and Care
Q1.8. Coinfection with HIV
Is there a designated governmental
unit/department re…
Q2.a. If yes, how many staff members does it have
Q2.b. Name of unit/department
How many people work full-time on
hepatitis-related a…
Did your government hold events for World
Hepatitis D…
Has your government funded any public viral
hepatitis…
Q5.a. General information about hepatitis and its transmi
Q5.b. Vaccination for hepatitis A and hepatitis B
Importance of knowing one’s hepatitis B and Q5.d. Safe water and good sanitation
Q5.e. Safer sex practices
Harm reduction for people who inject drugs Q5.g. Safe workplace practices
Q5.h. Other-please specify:
Q5.h. Others specified:
Does your government have a viral hepatitis
preventio…
Q6.a. Health workers (including health care waste handler
Q6.a. Comment
Q6.b. People who inject drugs
Q6.b. Comment
Q6.d. Prisoners
Q6.e. The homeless
Q6.g. Low-income populations
Q6.h. The uninsured
Does your government collaborate with any
civil socie…
Major partners specified
Is there routine surveillance for viral
hepatitis?
Q9.a. Hepatitis A
Q9.b. Hepatitis B
Q9.d. Hepatitis D
Q9.e. Hepatitis E
Q10.a. Hepatitis B
Q10.b. Hepatitis C
Q10.c. Hepatitis D
Questions 11-20
Do standard case definitions for hepatitis
infection…
A re deaths, including from hepatitis,
reported to a …
What percentage of hepatitis cases are
reported as “…
A re liver cancer cases registered?
A re cases of HIV /hepatitis co-infection
registered?
Q16.a. weekly
Q16.b. monthly
Q16.c. annual y
Q16.d. no reports published
Q16.e. other
Q16.e. Other listed
A re hepatitis outbreaks reported?
Q17.a. Are they further reported?
Is there a national public health research
agenda fo…
A re viral hepatitis sero - surveys conducted
regular…
Q19.a. How often?
Q19.b. When was the last one carried out?
Q19.c.1.Children (please specify age group): ___________…
Q19.c.1.Age group specified
Q19.c.2.General population
Q19.c.3.People who inject drugs
Q19.c.4.Men who have sex with men
Q19.c.5.Other groups
Q19.c.5.other groups specified
Is there adequate laboratory capacity
nationally to …
Q20.a. Hepatitis A
Q20.b. Hepatitis B
Q20.c. Hepatitis C
Q20.d. Hepatitis E
Questions 21-30
Is there a national hepatitis A vaccination
Q21.a. Travel ers to highly endemic countries
Q21.b. Military personnel
Q21.c. Children, as part of the national routine vaccinat…
Q21.d. Ecological and sanitary workers
Q21.e. Other – please specify
Q21.e. Others specified
Has your government established the goal
of eliminat…
Q22.a. If yes, in what timeframe?
Nationally, what percentage of newborn
infants in a …
Nationally, what percentage of one-year-
olds (ages 1…
Q25.Is. there a policy specifical y targetting MTCT of Hep…
Q25.a. Al pregnant women are screened for hepatitis B
Q25.b. Al pregnant women found to have hepatitis B are c
Q25.c. Health care providers fol ow up with al pregnant …
Q25.c. Comment
Q25.d. Upon delivery, al infants born to women with hepa
Q25.d. Comment
Q25.e. Al infants receive the first dose of hepatitis B …
Q25.e. Comment
Q25.f. Al infants receive the second and third doses of …
Q25.f. Comment
Is there a specific national strategy and/or
policy …
Q26.a. Are health workers vaccinated against hepatitis B …
Q26.a. Comment
Is there a national policy on injection safety
Q27.a.1.
What type of syringes does the policy recommend Q27.a.2.
What type of syringes does the policy recommend Q27.a.3.
What type of syringes does the policy recommend A re single-use or auto-disable syringes,
needles and…
What are your government’s official
Don't know
estimates of the…
Q29.a. Percentage (as a proportion of total injections ad…
Is there a national infection control policy for
Questions 31-40
A re all donated blood units (including family
donati…
A re all donated blood units (including family
donati…
Is there a national policy relating to the
preventio…
Does your government have guidelines
addressing how …
Q35.a. schools of health professionals (pre-service educa…
Q35.b. on-the-job training
Q35.c. Post-graduate training
Q35.d. other:
Q35.d. Other specified
Q35.e. do not know
Q36.a. Does your government have a national policy relati
Q36.b. Does your government have a national policy relati
Q37.1.a.
When testing, do people register by name (HepB) Q37.1.b.
When testing, do people register by name (HepC) Q37.1. Comment
Q37.2.aI.f people register by name, are their names kept…
Q37.2.bI.f people register by name, are their names kept…
Q37.2. Comment
Q37.3.aI.s the test free of charge for al individuals? …
Q37.3.bI.s the test free of charge for al individuals? …
Q37.3. Comment
Q37.4.aI.s the test free of charge for members of any sp…
Q37.4.a.
Q37.4.bI.s the test free of charge for members of any sp…
Q37.4.b.
Q37.5.aI.s the test compulsory for members of any specif
Q37.5.a.
Q37.5.bI.s the test compulsory for members of any specif
Q37.5.b.
Q37.5. Comment
A re there national clinical guidelines for the
manag…
Q38.a. If yes, do they include recommendations for cases
Q38.b. If no, are there national clinical guidelines for …
Is publicly funded treatment available for
hepatitis…
Q39.a. If yes, who is eligible for publicly funded treatm…
Is publicly funded treatment available for
hepatitis…
Q40.a. If yes, who is eligible for publicly funded treatm…
Questions 41-43
How much is spent by the government on
publicly fund…
Q42.a. at least one HepB treatment
Q42.a.1I.nterferon alpha
Q42.a.1.
Q42.a.2.
Q42.a.3.
Lamivudine (Epivir-HBV, Zeffix or Heptodin) Q42.a.4.
Q42.a.5.
Q42.a.6.
Q42.a.7.
Q42.a.8.
Q42.a.8.
Q42.b. at least 1 HepC treatment
Q42.b.1I.nterferon alpha
Q42.b.1.
Q42.b.2.
Q42.b.3.
Q42.b.4.
Q42.b.5.
Q42.b.6.
Q42.b. Others listed
Q43.a. Developing the national plan for viral hepatitis p…
Q43.b. Viral hepatitis surveil ance
Q43.c. Increasing coverage of the birth dose of the hepat
Q43.d. Estimating the national burden of viral hepatitis
Q43.e. Developing tools to assess the effectiveness of in…
Q43.f. Increasing access to treatment
Q43.g. Increasing access to diagnostics
Q43.h. Improving laboratory quality
Q43.i. Awareness-raising
Q43.j. Developing education/training programmes for
Q43.k. Assessing the economic impact of viral hepatitis
Q43.l. Integrating viral hepatitis programmes into other …
Q43.m.Other – please specify
Q43.m.Others specified
General.
Questions:
Questions 1-10
Q1. In your country, is there a written national strategy or plan that focuses exclusively or primarily on the prevention and control of viral hepatitis?** Please e-mail us the relevant supporting information.
Q1.a. Exclusive for viral hepatitis
Q1.b. only for hepatitis B
Q1.c. only for hepatitis C
Q1.d. Integrated with other diseases
Q1.e. Do not know
Q1.1. Raising awareness
Q1.2. Surveillance
Q1.3. Vaccination
Q1.4. Prevention in general
Q1.5. prevention of transmission of viral hepatitis via injecting drug use
Q1.6. Health care transmission prevention
Q1.7. Treatment and Care
Q1.8. Coinfection with HIV
Q1. comment
Q2. Is there a designated governmental unit/department responsible only for coordinating and/or carrying out viral hepatitis-related activities?
Q2.a. If yes, how many staff members does it have
Q2.b. Name of unit/department
Q2. comment
Q3. How many people work full-time on hepatitis-related activities in all government agencies/bodies?
Q3. Comment
Q4. Did your government hold events for World Hepatitis Day 2012?*
Q4. Comment
Q5. Has your government funded any public viral hepatitis awareness campaigns since January 2011, other than World Hepatitis Day?*
Q5.a. General information about hepatitis and its transmission
Q5.b. Vaccination for hepatitis A and hepatitis B
Q5.c. Importance of knowing one’s hepatitis B and hepatitis C status
Q5.d. Safe water and good sanitation
Q5.e. Safer sex practices
Q5.f. Harm reduction for people who inject drugs
Q5.g. Safe workplace practices
Q5.h. Other-please specify:
Q5.h. Others specified:
Q5. Comment
Q6. Does your government have a viral hepatitis prevention and control program that includes activities targetting specific populations?
Q6. Comment
Q6.a. Health workers (including health care waste handlers)
Q6.a. Comment
Q6.b. People who inject drugs
Q6.b. Comment
Q6.c. Migrants
Q6.d. Prisoners
Q6.e. The homeless
Q6.f. People living with HIV
Q6.g. Low-income populations
Q6.h. The uninsured
Q6.i. Indigenous people
Q6.j. Other
Q6.j. Other- please specify
Q7. Does your government collaborate with any civil society groups within your country (such as patient groups or national or local nongovernmental organisations) to develop and implement its viral hepatitis prevention and control programme? If yes, please
name major partners.
Q7. Major partners specified
Q7. Comment
Q8. Is there routine surveillance for viral hepatitis?
Q9.a. Hepatitis A
Q9.b. Hepatitis B
Q9.c. Hepatitis C
Q9.d. Hepatitis D
Q9.e. Hepatitis E
Q9. comment
Q10.a. Hepatitis B
Q10.b. Hepatitis C
Q10.c. Hepatitis D
Questions 11-20
Q11. Do standard case definitions for hepatitis infections exist?
Q11. Comment
Q12. A re deaths, including from hepatitis, reported to a central registry?
Q12. Comment
Q13. What percentage of hepatitis cases are reported as “undifferentiated” or “unclassified” hepatitis?
Q13. Comment

Q14. A re liver cancer cases registered?
Q14. Comment
Q15. A re cases of HIV /hepatitis co-infection registered?
Q15. Comment
Q16.a. weekly
Q16.b. monthly
Q16.c. annually
Q16.d. no reports published
Q16.e. other
Q16.e. Other listed
Q16. Comment
Q17. A re hepatitis outbreaks reported?
Q17.a. A re they further reported?
Q17. comment
Q18. Is there a national public health research agenda for viral hepatitis?*
Q18. Comment
Q19. A re viral hepatitis sero - surveys conducted regularly?
Q19. Comment
Q19.a. How often?
Q19.b. When was the last one carried out?
Q19.c.1. Children (please specify age group): ______________________
Q19.c.1 A ge group specified
Q19.c.2. General population
Q19.c.3. People who inject drugs
Q19.c.4 Men who have sex with men
Q.19.c.5. Other groups
Q.19.c.5. other groups specified
Q20. Is there adequate laboratory capacity nationally to support viral hepatitis outbreak investigations and other surveillance activities?
Q20.a. Hepatitis A
Q20.b. Hepatitis B
Q20.c. Hepatitis C
Q20.d. Hepatitis E
Q20. Comment
Questions 21-30
Q21. Is there a national hepatitis A vaccination policy?
Q21. Comment
Q21.a. Travellers to highly endemic countries
Q21.b. Military personnel
Q21.c. Children, as part of the national routine vaccination program
Q21.d. Ecological and sanitary workers
Q21.e. Other – please specify
Q21.e. Others specified
Q22. Has your government established the goal of eliminating hepatitis B?
Q22.a. If yes, in what timeframe?
Q22. Comment
Q23. Nationally, what percentage of newborn infants in a given recent year received the first dose of hepatitis B vaccine within 24 hours of birth?
Q23. Comment
Q24. Nationally, what percentage of one-year-olds (ages 12-23 months) in a given recent year received three doses of hepatitis B vaccine?
Q24. Comment
Q25.Is there a policy specifically targetting MTCT of HepB?
Q25. Comment
Q25.a. A ll pregnant women are screened for hepatitis B
Q25.b. A ll pregnant women found to have hepatitis B are counselled
Q25.c. Health care providers follow up with all pregnant women found to have hepatitis B during pregnancy for the purpose of encouraging them to give birth at health care facilities
Q25.c. Comment
Q25.d. Upon delivery, all infants born to women with hepatitis B receive hepatitis B immunoglobulin
Q25.d. Comment
Q25.e. A ll infants receive the first dose of hepatitis B vaccine within 24 hours of birth
Q25.e. Comment
Q25.f. A ll infants receive the second and third doses of hepatitis B vaccine within 12 months of birth
Q25.f comment
Q26. Is there a specific national strategy and/or policy for preventing hepatitis B and hepatitis C infection in healthcare settings?
Q26. comment
Q26.a. A re health workers vaccinated against hepatitis B prior to starting work that might put them at risk of exposure to blood?
Q26.a. Comment
Q27. Is there a national policy on injection safety in health care settings?
Q27. comment
Q27.a.1. What type of syringes does the policy recommend for therapeutic injections? (single-use syringes)
Q27.a.2. What type of syringes does the policy recommend for therapeutic injections? (auto-disable syringes)
Q27.a.3. What type of syringes does the policy recommend for therapeutic injections? (do not know)
Q28. A re single-use or auto-disable syringes, needles and cannulas always available in all healthcare facilities?
Q28. Comment
Q29. What are your government’s official estimates of the number of unnecessary injections administered annually in health care settings? (e.g., injections that are given when an equivalent oral medication is available)

Q29. comment
Q29.a. Percentage (as a proportion of total injections administered annually in health care settings)
Q30. Is there a national infection control policy for blood banks?*
Q30. Comment
Questions 31-40
Q31. A re all donated blood units (including family donations) and blood products nationwide screened for hepatitis B?
Q32. A re all donated blood units (including family donations) and blood products nationwide screened for hepatitis C?
Q33. Is there a national policy relating to the prevention of viral hepatitis among people who inject drugs?*
Q33. Comment
Q34. Does your government have guidelines addressing how hepatitis A and hepatitis E can be prevented through food and water safety?
Q34. Comment
Q35.a. schools of health professionals (pre-service education)
Q35.b. on-the-job training
Q35.c. Post-graduate training
Q35.d. other:
Q35.d. Other specified
Q.35.e. do not know
Q36.a. Does your government have a national policy relating to screening and referral to care for Hepatitis B?*
Q36.b. Does your government have a national policy relating to screening and referral to care for Hepatitis C?*
Q36. Comment
Q37.1.a. When testing, do people register by name (HepB)
Q37.1.b. When testing, do people register by name (HepC)
Q37.1. Comment
Q37.2.a. If people register by name, are their names kept confidential within the system, or is there open access? (HepB)
Q37.2.b. If people register by name, are their names kept confidential within the system, or is there open access? (HepC)
Q.37.2. Comment
Q37.3.a. Is the test free of charge for all individuals? (HepB)
Q37.3.b. Is the test free of charge for all individuals? (HepC)
Q37.3. Comment
Q37.4.a. Is the test free of charge for members of any specific groups? (HepB)
Q37.4.a. Groups specified
Q37.4.b. Is the test free of charge for members of any specific groups? (HepC)
Q37.4.b. Groups specified
Q37.5.a. Is the test compulsory for members of any specific groups? (Hep B)
Q37.5.a. Groups specified
Q37.5.b. Is the test compulsory for members of any specific groups? (HepC)
Q37.5.b. Groups specified
Q37.5. Comment
Q38. A re there national clinical guidelines for the management of viral hepatitis?*
Q38.a. If yes, do they include recommendations for cases of HIV co-infection?
Q38.b. If no, are there national clinical guidelines for the management of HIV that include recommendations for coinfection with viral hepatitis?
Q38. comment
Q39. Is publicly funded treatment available for hepatitis B?
Q39.a. If yes, who is eligible for publicly funded treatment for hepatitis B? Please specify:
Q39. comment
Q40. Is publicly funded treatment available for hepatitis C?
Q40.a. If yes, who is eligible for publicly funded treatment for hepatitis C? Please specify:
Q40. Comment
Questions 41-43
Q41. How much is spent by the government on publicly funded treatment for hepatitis B and hepatitis C? (Please indicate currency. Please also indicate whether the amount is for one or both of the infections.)
Q41. Comment
Q42.a. at least one HepB treatment
Q42.a.1. Interferon alpha
Q42.a.1. Comment
Q42.a.2. Pegylated interferon
Q42.a.3. Lamivudine (Epivir-HBV, Zeffix or Heptodin)
Q42.a.4. A defovir dipivoxil (Hepsera)
Q42.a.5. Entecavir (Baraclude)
Q42.a.6. Telbivudine (Tyzeka, Sebivo)
Q42.a.7. Tenofovir (V iread)
Q42.a.8. Other
Q42.a.8. Others listed
Q42.b. at least 1 HepC treatment
Q42.b.1. Interferon alpha
Q42.b.1. Comment
Q42.b.2. Pegylated interferon
Q42.b.3. Ribavirin
Q42.b.4. Boceprevir (V ictrelis)
Q42.b.5. Telaprevir (Incivo, Incivek)
Q42.b.6. Other:
Q42.b. Others listed
Q42. Comment
Q43.a. Developing the national plan for viral hepatitis prevention and control

Q43.b. V iral hepatitis surveillance
Q43.c. Increasing coverage of the birth dose of the hepatitis B vaccine
Q43.d. Estimating the national burden of viral hepatitis
Q43.e. Developing tools to assess the effectiveness of interventions
Q43.f. Increasing access to treatment
Q43.g. Increasing access to diagnostics
Q43.h. Improving laboratory quality
Q43.i. A wareness-raising
Q43.j. Developing education/training programmes for health professionals
Q43.k. A ssessing the economic impact of viral hepatitis
Q43.l. Integrating viral hepatitis programmes into other health services
Q43.m. Other – please specify
Q43.m. Others specified
General comments

Source: http://global-report.worldhepatitisalliance.org/api/pdf/pdf:4ef49839903d181dfe791bc4d483b16f/Viral_Hepatitis-Global_Policy.pdf

healthtrioconnect.com2

September 2012 CVS Caremark Value Priced Generics List The CVS Caremark Value Priced Generics Drug List offers Capital Health Plan members access to a 30-day supply of select maintenance generic medications under the member's prescription benefit plan and can be fil ed at any retail store in the pharmacy network. Capital Health Plan members may receive a 90-day supply from a particip

Microsoft word - a-1-8-rasoanaivo

11th NAPRECA Symposium Book of Proceedings, Antananarivo, Madagascar Natural Products and Drug Discovery through a Network of Partnerships Philippe Rasoanaivo, David Ramanitrahasimbola, Dina Rakotondramanana, Voahangy Ramanandraibe, Suzanne Ratsimamanga Institut Malgache de Recherches Appliquées Abstract We present here relevant result obtained from a network of collaborations. Mala

Copyright © 2010-2014 Pharmacy Drugs Pdf